首页 | 本学科首页   官方微博 | 高级检索  
     

齐拉西酮与利培酮治疗首发精神分裂症疗效与安全性的系统评价
引用本文:范小冬,谢星星,张杰,张春燕,孔文强,杜彪. 齐拉西酮与利培酮治疗首发精神分裂症疗效与安全性的系统评价[J]. 川北医学院学报, 2017, 32(2): 197-201. DOI: 10.3969/j.issn.1005-3697.2017.02.013
作者姓名:范小冬  谢星星  张杰  张春燕  孔文强  杜彪
作者单位:1. 川北医学院药学院,四川 南充,637000;2. 西南医科大学药学院,四川 泸州,646000;3. 南部县人民医院药剂科,四川 南部,637300;4. 川北医学院药学院,四川 南充 637000;重庆三峡中心医院药学部,重庆 404000
基金项目:重庆市社会事业与民生保障科技创新专项,重庆市万州区科技计划基金资助项目
摘    要:目的:系统评价齐拉西酮与利培酮治疗首发精神分裂症患者的疗效与安全性,为临床治疗提供循证参考。方法:计算机检索Pub Med、EMbase、EBSCO、CBM、CNKI、VIP和Wan Fang Data,收集齐拉西酮(试验组)对比利培酮(对照组)治疗首发精神分裂症患者的随机对照试验(RCT),对符合纳入标准的临床研究进行资料提取和质量评价后,采用Rev Man 5.0统计软件进行Meta分析。结果:共纳入29篇RCT,合计2 424例患者。Meta分析结果显示,试验组患者痊愈率和总显效率与对照组比较,差异无统计学意义(P>0.05);不良反应方面,试验组发生体重增加[P<0.001,OR合并=0.19,95%CI=(0.13,0.29)]、泌乳素升高[P<0.001,OR合并=0.08,95%CI=(0.05,0.14)]及锥体外系反应[P=0.000 7,OR合并=0.37,95%CI=(0.21,0.66)]均低于对照组,差异有统计学意义,试验组发生心电图异常[P=0.002,OR合并=2.59,95%CI=(1.44,4.65)]及头痛[P=0.02,OR合并=1.85,95%CI=(1.11,3.11)]高于对照组,差异有统计学意义。结论:两药治疗首发精神分裂症疗效相当,齐拉西酮发生锥体外系反应和代谢紊乱较利培酮少,而心电图异常与头痛的发生率较利培酮多。受纳入研究方法学质量和样本量限制,该结论有待更多设计严格、长期随访的大样本RCT加以验证。

关 键 词:齐拉西酮  利培酮  首发精神分裂症  系统评价  Meta分析

Systematic review of the efficacy and safety of Ziprasidone and Risperidone in the treatment of first episode schizophrenia
FAN Xiao-dong,XIE Xing-xing,ZHANG Jie,ZHANG Chun-yan,KONG Wen-qiang,DU Biao. Systematic review of the efficacy and safety of Ziprasidone and Risperidone in the treatment of first episode schizophrenia[J]. Journal of North Sichuan Medical College, 2017, 32(2): 197-201. DOI: 10.3969/j.issn.1005-3697.2017.02.013
Authors:FAN Xiao-dong  XIE Xing-xing  ZHANG Jie  ZHANG Chun-yan  KONG Wen-qiang  DU Biao
Abstract:Objective:To systematically review the efficacy and safety of Ziprasidone versus Risperidone in the treatment of first-episode schizophrenia,and provide evidence-based reference for clinical treatment.Methods:Searched the clinical control study of the Ziprasidone and Risperidone in the treatment of first-episode schizophrenia by pubmed,EMbase,EBSCO,CBM,CNKI,VIP and WanFang data bank.After quality evaluation and data extract,meta-analysis was performed by using Rev Man 5.0 statistics software.Results: A total of 29 RCT were included,involving 2 424 patients.Results of meta-analysis showed that the efficacy rate and the total efficiency rate of Ziprasidone and Risperidone had no significant difference(P>0.05);In the adverse drug reactions,the incidences of extrapyramidal reactions[P=0.000 7,OR=0.37,95%CI=(0.21,0.66)],the incidences of weight gain[P<0.001,OR=0.19,95%CI=(0.13,0.29)] and the incidences of prolactin increasing[P<0.001,OR=0.08,95%CI=(0.05,0.14)] of control group were significantly more than test group with statistically significant difference;the incidences of headache[P=0.02,OR=1.85,95%CI=(1.11,3.11)] and the incidences of electrocardiographic abnormality[P=0.002,OR=2.59,95%CI=(1.44,4.65)] were significantly lower than test group with statistically significant difference.Conclusion: The efficacy of the Ziprasidone and Risperidone in the treatment of first episode schizophrenia is similar,the incidences of extrapyramidal reaction metabolic disorders less risperidone,and the incidences of headache and abnormal electrocardiogram more than risperidone.Because of limited method logical quality and sample size,it remains to be further verified with more rigorously designed and long-term follow-up of large-scale RCT.
Keywords:Ziprasidone  Risperidone  First episode schizophrenia  Systematic review  Meta-analysis
本文献已被 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号